MedPath

Clinical evalution of Oma Ilagam (Internal) and Sangamver Thylam (External)for the managaement of Kalanjapadai(Psoriasis) in childre

Phase 2
Completed
Conditions
Health Condition 1: L409- Psoriasis, unspecified
Registration Number
CTRI/2021/08/035820
Lead Sponsor
OPD IPD Ayothidoss Pandithar hospital National institite of siddha
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Patient with two or more of the following symptoms

Scaling

Erythema

With or without itching

Candle crease sign positive

Dryness of skin

Cracks followed by itching

Auspitz sign positive

Thickness

Exclusion Criteria

Psoriatic arthritis

Eczema

Psoriasis with evidence od any other skin disease

Fungal infection

Any other systemic disorder

Lesion with secondary infection

Epilepsy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efiicacy of the trial drug is measured by PASI score and improvement in the clinical condition is assured by reducing the degrees of involvement of the body region from 5 to 1Timepoint: 45 days
Secondary Outcome Measures
NameTimeMethod
Reduction in the remission of the disease and improvement in the qualitu of life in children <br/ ><br>Quality of life will be measured with standard published questionarieTimepoint: Before and after treament assessment in interval of 45 days
© Copyright 2025. All Rights Reserved by MedPath